References
- Griffin JD, Lowenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood 1986;68:1185–1195.
- Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colonystimulating factor with low-dose cytosine arabinoside and for previously treated acute myelogenous leukemia: a pilot study. Leukemia 1995;9:10–14.
- Wu L, Li X, Su J, et al. Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS. J Cancer Res Clin Oncol 2011;137: 1563–1569.
- Gu LF, Zhang WG, Wang FX, et al. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. J Cancer Res Clin Oncol 2011;137:997–1003.
- Tan CT, Luks E, Bacha DM, et al. Phase I trial of homoharringtonine in children with refractory leukemia. Cancer Treat Rep 1987;71: 1245–1248.
- Liu H, Qian WB, Mai WY, et al. HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia. Zhonghua Xue Ye Xue Za Zhi 2008;29:9–12.
- Larsen A, Davis T, Curtis BM, et al. Expression cloning of a human granulocyte colony-stimulating factor receptor: a structural mosaic of hematopoietin receptor, immunoglobulin and fibronectin domains. J Exp Med 1990;172:1559–1570.
- Xue YP, Bian SG, Zhao YZ, et al. Sizu sanyaolianhefangan zhiliao chenrenjixingsuixibaixuebing liaoxiaobijiao [Effectiveness comparison of four triple-drug regimens as induction chemotherapy in the treatment of adult patients with acute myeloid leukemia].Zhonghua Xueyexue Zazhi 2002;23:33–34.
- Mato AR, Morgans A, Luger SM. Novel strategies for relapsed and refractory acute myeloid leukemia. Curr Opin Hematol 2008;15: 108–114.
- Edward A, Barry C, Houston H, et al. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist 2011;16:197–206.
- Bai A, Kojima H, Hori M, et al. Priming with G-CSF enhance low-dose Ara-C-induced in vivo apoptosis in myeloid leukemic cell. Exp Hematol 1997;27:259–265.
- Cai Z, Lin M, Wuchter C, et al. Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation. Leukemia 2001;15:567–574.
- Zhou DC, Zittoun R, Marie JP. Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull Cancer 1995;82: 987–995.
- Mai WY, Lin MF. Induction of apotosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells. Chin Med J 2005;118:487–492.
- Liu H, Qian WB, Mai WY, et al. Yi HAA fang’an zhiliao chengren chufangjixing suixibaixuebing liaoxiaoguancha [HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia].Zhonghua Xueyexue Zhazhi 2008;29:9–12.